Although FOXO1 must be excluded from the nucleus becoming inactive in myoblasts during myogenesis [22], we found FOXO1 expressed in the nuclei of all ALS patient myoblasts as well as in TDP-43- or FUS-silenced myoblasts, suggesting this change as a consistent pathogenic feature in ALS muscle. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.